Related Experiment Videos
Disseminated intravascular coagulation: What's new?
1Department of Vascular and Internal Medicine (F-4), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. m.m.levi@amc.uva.nl
Critical Care Clinics
|July 5, 2005
Summary
Disseminated intravascular coagulation (DIC) is a critical condition involving systemic coagulation activation, fibrin deposition, and consumption of clotting factors. Understanding its pathways informs new anticoagulant and pathway restoration therapies.
Area of Science:
- Hematology
- Pathophysiology
- Medical Science
Background:
- Disseminated intravascular coagulation (DIC) is a complex syndrome.
- It involves systemic coagulation activation, leading to fibrin deposition in microvasculature.
- This process consumes coagulation factors and platelets, linking DIC to organ dysfunction.
Purpose of the Study:
- To elucidate the pathogenetic mechanisms of DIC.
- To highlight the role of microvascular thrombosis in organ dysfunction.
- To discuss novel therapeutic strategies for DIC.
Main Methods:
- Review of pathological, experimental, and clinical findings.
- Analysis of pathogenetic pathways including coagulation activation, anticoagulant pathways, and fibrinolysis.
- Evaluation of emerging therapeutic approaches.
Main Results:
- DIC pathogenesis involves tissue factor-dependent coagulation activation.
- Defects in physiological anticoagulant pathways (antithrombin, protein C) contribute to DIC.
- Impaired fibrinolysis, due to elevated plasminogen activator inhibitor type 1, is also implicated.
Conclusions:
- Insights into DIC pathogenesis are driving novel therapeutic strategies.
- Therapeutic approaches include anticoagulation targeting tissue factor.
- Restoring physiological anticoagulant pathways, such as with activated protein C concentrate, is a key strategy.